Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wyeth Pharmaceuticals, a division of Wyeth has terminated its collaboration agreements with Solvay Pharmaceuticals for the development and commercialization of bifeprunox as well as other compounds in earlier stages of development for the potential treatment of schizophrenia and other psychiatric conditions.
Subscribe to our email newsletter
Wyeth terminated the collaboration with Solvay after assessing the opportunity for bifeprunox and determining it would not have sufficient commercial value for the two companies to share. All development and commercialization rights in North America for bifeprunox, an investigational atypical antipsychotic, as well as global rights for the other compounds will now revert to Solvay Pharmaceuticals.